Meeting
2018 ASCO Annual Meeting
Treatment of metastatic uveal melanoma (mUM) directed by a comprehensive molecular tumour analysis program (CMTA).
Authors
Serge Leyvraz
Charité Comprehensive Cancer Center, Berlin, Germany
Serge Leyvraz , Thomas Kessler , Moritz Schütte , Mario Lamping , Susen Burock , Sebastian Ochsenreither , Vyacheslav Amstislavskiy , Christoph Wierling , Korinna Jöhrens , Frederick Klauschen , Caroline-Anna Peuker , Felix Kiecker , Reinhold Schäfer , Bodo Lange , Hans Lehrach , Antonia Joussen , Damian Tobias Rieke , Konrad Friedrich Klinghammer , Ulrich Keilholz , Marie-Laure Yaspo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
EA4/063/13
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9566)
DOI
10.1200/JCO.2018.36.15_suppl.9566
Abstract #
9566
Poster Bd #
393
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.
First Author: Douglas Buckner Johnson
Poster
2024 ASCO Annual Meeting
Association between clinical and disease characteristics and detectable or undetectable baseline ctDNA in patients with metastatic uveal melanoma.
First Author: Paul D. Nathan
Poster
2022 ASCO Annual Meeting
Outcomes of combined ipilimumab/nivolumab in metastatic uveal melanoma: A prevalence meta-analysis.
First Author: Ceren Durer
Poster
2022 ASCO Annual Meeting
Distinct mutational landscapes characterize melanomas metastatic to different anatomical sites.
First Author: Mahesh Y. Iddawela